HolderBook

Defilade Capital Management, L.P.

Reported holdings as of Q2 2026, from 3 quarterly filings.

CIK
2088557
Reported value
$746.9M
Positions
39
Top 10 weight
46.5%
Filed
2026-08-14
Days after quarter end
45

Holdings

SecurityTickerValue SharesWeightWeight change Held Change
ELI LILLY & COLLY$46.9M39,0866.28%+3.60pp3q+88.9%+$22.1M
PFIZER INCPFE$42.7M1,771,7435.71%+2.99pp3q+21.0%+$7.4M
VEEVA SYS INCVEEV$42.0M236,7095.62%-newNEW
BIOMARIN PHARMACEUTICAL INCBMRN$39.0M682,0055.22%-newNEW
PTC THERAPEUTICS INCPTCT$35.4M433,6994.74%-1.04pp2q+15.3%+$4.7M
BAXTER INTL INCBAX$31.1M1,459,3804.17%-newNEW
INSMED INCINSM$30.0M281,8384.02%-0.45pp3q+44.6%+$9.3M
ZIMMER BIOMET HOLDINGS INCZBH$27.3M317,4263.66%-3.69pp2q-45.2%-$22.5M
INSULET CORPPODD$26.9M176,9323.61%-newNEW
THERMO FISHER SCIENTIFIC INCTMO$26.0M51,9343.49%-newNEW
ABBOTT LABORATORIESABT$25.9M285,7783.47%-newNEW
ASCENDIS PHARMA A/SASND$25.3M94,8433.39%-newNEW
SOLVENTUM CORPSOLV$24.4M316,4543.27%-newNEW
MEDTRONIC PLCMDT$23.7M303,3013.18%-newNEW
ELANCO ANIMAL HEALTH INCELAN$21.3M864,0802.85%-0.28pp3q-7.2%-$1.6M
AGIOS PHARMACEUTICALS INCAGIO$20.3M546,8482.72%-newNEW
ENVISTA HOLDINGS CORPORATIONNVST$19.1M726,1082.56%-newNEW
REVOLUTION MEDICINES INCRVMD$15.5M82,8272.08%-2.24pp3q-73.8%-$43.7M
ICU MED INCICUI$15.5M105,7002.07%-2.54pp3q-58.4%-$21.8M
COGENT BIOSCIENCES INCCOGT$15.2M393,4412.04%+0.13pp3q+11.6%+$1.6M
LANTHEUS HLDGS INCLNTH$14.7M132,6621.97%-0.69pp2q-46.8%-$13.0M
OCULAR THERAPEUTIX INCOCUL$14.6M1,490,2861.96%+0.19pp3qHELD
ELEDON PHARMACEUTICALS INCELDN$13.9M3,525,3381.86%+0.32pp3q-1.1%-$152.8K
TYRA BIOSCIENCES INCTYRA$12.0M376,8701.61%-newNEW
OLEMA PHARMACEUTICALS INCOLMA$11.6M924,7581.55%-1.60pp3q-38.5%-$7.3M
ORIC PHARMACEUTICALS INCORIC$11.3M1,047,6901.52%+0.02pp2q+24.3%+$2.2M
LARIMAR THERAPEUTICS INCLRMR$11.2M3,670,1351.50%-newNEW
GLOBUS MED INCGMED$11.0M139,6371.48%-2.81pp3q-60.6%-$17.0M
ENOVIS CORPORATIONENOV$11.0M531,9451.47%-newNEW
EVOMMUNE INCEVMN$10.5M793,1451.41%-0.78pp3q+16.9%+$1.5M
TELEFLEX INCORPORATEDTFX$10.2M80,1181.36%-newNEW
DENALI THERAPEUTICS INCDNLI$10.1M391,8661.35%-2.32pp3q-71.2%-$24.9M
GLAUKOS CORPGKOS$9.3M66,5191.24%-newNEW
STAAR SURGICAL COSTAA$9.2M322,1261.24%-newNEW
PACS GROUP INCPACS$9.2M215,6751.23%-2.37pp3q-64.3%-$16.6M
CRINETICS PHARMACEUTICALS INCRNX$9.0M239,4401.20%-newNEW
LIVANOVA PLCLIVN$8.8M107,3731.18%-newNEW
BLACK DIAMOND THERAPEUTICS IBDTX$3.1M1,674,9990.41%-newNEW
MEREO BIOPHARMA GROUP PLCMREO$2.4M7,558,7560.32%-0.03pp2qHELD

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 59.2%Medical Devices 30.5%Software & IT Services 5.6%Instruments & Controls 3.5%Other sectors 1.2%
 
SectorValueShare
Biotech & Pharma$442.0M59.2%
Medical Devices$227.7M30.5%
Software & IT Services$42.0M5.6%
Instruments & Controls$26.0M3.5%
Other sectors$9.2M1.2%

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2026$746.9M39207101246.5%45
Q1 2026$712.2M31912101152.6%44
Q4 2025$737.7M33000055.1%44

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.